ZK824859 (2 mg/kg; PO) exhibits a relatively high oral availability and a moderate half time (T1/2=2.8 h)[1]. Animal Model: Rats with experimental autoimmune encephalomyelitis (EAE) model[1] Dosage: 2 mg/kg (Pharmacokinetic Analysis) Administration: PO Result: Oral availability F = 55%; Cmax= 0.64 g/mL and AUC = 2.2 h*g/mL; T1/2=2.8 h.
In Vitro
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
